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Strengths and limitations of this study
 ► Systematic review and core outcome set (COS) de-
velopment methods that adhere to Core Outcome 
Measures in Effectiveness Trials (COMET) guidelines.
 ► Plans to engage with multiple stakeholders to 
generate diverse viewpoints with worldwide 
representation.
 ► Key study staff representing international 
collaboration.
 ► This study will not involve a qualitative dimension 
and the study components will be limited to the 
English language.
 ► As a repository of definitions already exists, this 
study will not address how to measure the outcomes 
included in the final COSs.
AbStrACt
Introduction Selective reporting bias, inconsistency in 
the chosen outcomes between trials and irrelevance of the 
chosen outcomes for women, limit the efficiency and value 
of research for prevention and treatment of gestational 
diabetes mellitus (GDM). One way to address these 
challenges is to develop core outcome sets (COSs).
Methods and analysis The aim of this manuscript is to 
present a protocol for a study to develop COSs for GDM 
prevention and treatment. This is a three- phase project 
consisting of (1) a systematic review of the literature to 
create two lists of outcomes that have been reported in 
trials and systematic reviews of trials of interventions for 
the prevention and treatment of GDM, (2) a three- round, 
web- based e- Delphi survey with key stakeholders to 
prioritise these outcomes and (3) a consensus meeting to 
resolve any remaining disagreements and to agree on two 
COSs.
Ethics and dissemination Ethical approval to conduct 
this study was obtained from the ethics committee 
at Galway University Hospitals on 13 December 2018 
(Reference: C.A.2078). We will disseminate our research 
findings through peer- reviewed, open access publications 
and present at international conferences to reach a wide 
range of knowledge users.
IntroduCtIon
Gestational diabetes mellitus (GDM) is the 
occurrence of glucose intolerance during 
pregnancy and usually resolves after birth.1 It 
is one of the major conditions contributing 
to maternal morbidity and fetal and neonatal 
mortality and morbidity. There is recognition 
of increasing prevalence of GDM worldwide, 
with prevalence ranging between 1% and 
16.9% across countries depending on the 
criteria of diagnosis.2 3
GDM is associated with short- term and 
long- term complications for the mother and 
her infant with wider health and economic 
burden.4–14 The aim of GDM management is 
to optimise maternal glycaemic control and 
consequently improve pregnancy outcomes.15 
Lifestyle advice and dietary interventions 
are usually recommended as the primary 
therapeutic strategy for women with GDM. 
If this strategy is insufficient, oral hypogly-
caemic medications or insulin therapy can be 
added to achieve target glycaemic control.15 
However, treatment recommendations differ 
between, and also within, countries.
The burden of GDM has resulted in an 
increase in randomised trials of interven-
tions for the prevention and treatment 
of GDM in recent years. For instance, 
MEDLINE included <1700 citations indexed 
as ‘gestational diabetes mellitus’ before 2000, 
compared with >3000 citations between 
2001 and 2010.16 In addition, the majority 
of randomised trials on GDM have been 
published in the last 10 years.16
Heterogeneity in the outcomes reported in 
the trials makes combining and comparing 
results between trials difficult.17 Conse-
quently, this may limit the validity of meta- 
analysis and reliability of evidence. A recent 
Cochrane review by Brown et al (2017) of 
15 trials (4501 women, 3768 infants) evalu-
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interventions, with or without pharmacotherapy, for 
treating women with GDM, identified the main meth-
odological limitation as the inconsistency in outcome 
reporting in the included trials.15 A recent systematic 
review, evaluating the effects of oral antidiabetic medica-
tions for treating women with GDM, included 11 studies 
(1487 women and their offspring), and stated that there 
was substantial heterogeneity in the outcomes reported 
across trials included in the review.18
Selective reporting bias occurs when additional 
outcomes that were not prespecified are reported; or 
where outcomes that had been prespecified are not 
reported. For example, a randomised trial of a carbose 
versus placebo in the treatment of GDM reported many 
more maternal and neonatal outcomes in the published 
paper than were prespecified in the trial registration 
document.19 Fully informed decisions about care cannot 
be made based on research with selective reporting of 
outcomes as this could lead to use of ineffective and 
sometimes harmful interventions, and under use of inter-
ventions that might be effective. This means selection of 
results that cover only a fraction of relevant evidence can 
lead to inappropriate decisions, for example, prescribing 
ineffective treatment or not prescribing effective 
treatment.
Last, outcomes reported in literature may not reflect 
the values and preferences of study participants. For find-
ings to influence policy and practice, outcomes need to 
be relevant and important to key stakeholders and, in 
particular, women. One study on women’s attitudes and 
perspectives on dietary advice as a strategy in the manage-
ment of GDM found that stress and anxiety were reported 
as important outcomes following dietary advice from the 
perspective of the women.20 These outcomes are rarely 
reported in the existing GDM management literature. 
Using relevant outcomes for women and other stake-
holders in GDM, this research will enhance pregnancy 
care and improve maternal and offspring health.
The development of core outcome sets (COSs) for 
evaluating the effectiveness of interventions for the 
prevention and treatment of GDM would help minimise 
heterogeneity in outcomes reported, maximise potential 
for synthesising of information and ensure that all stake-
holders’ perspectives are represented in the outcomes 
reported. The COS represents the minimum set of 
outcomes that are expected to always be measured and 
reported, though, trialists are not restricted to these set 
of outcomes as they can measure additional outcomes. 
At the outset, potential barriers to COS implementation 
should be considered, and in this particular scenario, 
generating a list of key outcomes with worldwide rele-
vance may be challenging.
The Core Outcome Measures in Effectiveness Trials 
(COMET) handbook21 and the Core Outcome Set- 
STAndards for Development (COS- STAD)22 brings 
together the current thinking and methodological 
research on this subject and provides minimal standards 
to be followed by COS developers. Relevant to the subject 
of GDM, the Core Outcomes in Women’s and Newborn 
Health initiative advocates for the development of COSs 




To present a protocol for a study to develop two COSs 
- one for trials evaluating interventions for the prevention 
of GDM and another for trials evaluating interventions 
for treatment of GDM.
Objectives
1. To conduct a systematic review to identify two compre-
hensive lists of outcomes used previously in trials eval-
uating the effectiveness of interventions for both the 
prevention and treatment of GDM.
2. Prioritisation and generation of two lists of outcomes 
based on the preferences of relevant stakeholder 
groups using e- Delphi methodology.
3. Achieve a consensus on two COSs through a face- to- 
face meeting.
Scope of the CoS
The first COS will be developed for effectiveness trials 
evaluating any intervention for prevention of GDM, and 
the second COS will be developed for effectiveness trials 
evaluating any intervention for treatment of GDM.
Other forms of diabetes mellitus are outside the scope 
of these COSs.
Study oversight
An international study advisory group (SAG) has been 
established. The SAG includes representatives from 
researchers (n=2), healthcare professionals (an endocri-
nologist and an obstetrician), (n=2) and women with a 
previous diagnosis of GDM (n=2). The remit of the SAG 
is to oversee the study, provide feedback on the study 
protocol and list of outcomes, assist with circulation of the 
e- Delphi survey and to contribute to the final consensus 
meeting and distribution of the COSs.
MEthodS And AnAlySIS
The development of COSs will be conducted within 
three discrete work packages (figure 1) in keeping with 
COMET guidance and COS- STAD recommendations21 22:
1. A systematic review of the literature to identify out-
comes that have been reported in trials and systematic 
reviews of trials of interventions for the prevention and 
treatment of GDM.
2. A three- round, web- based, e- Delphi survey with key 
stakeholders to prioritise outcomes.
3. A consensus meeting to finalise the COSs.
Patient and public involvement (PPI)
This study will be supported by PPI and both the core 
study team and the SAG containing patient representa-




















pen: first published as 10.1136/bm






3Egan AM, et al. BMJ Open 2019;9:e030574. doi:10.1136/bmjopen-2019-030574
Open access
Figure 1 Overview of the COS development process. COS, core outcome set; GDM, gestational diabetes mellitus.
will participate in the e- Delphi survey and the consensus 
meeting.
Systematic review of trials and systematic reviews of trials
To identify outcomes used previously in trials, we will 
perform a systematic review of randomised trials and 
systematic reviews of randomised trials evaluating 
the effectiveness of interventions for the prevention 
and treatment of GDM. The systematic review will be 
performed in stages until outcome saturation is reached. 
A search will be performed for eligible studies from 2015 
to 2019. Outcomes from 2017 to 2019 studies will be 
indexed initially and then outcomes from 2016 studies 
will be added. If no additional unique outcomes are iden-
tified from the 2016 studies, outcome saturation will be 
reached. If outcome saturation is not reached, outcomes 
from the 2015 studies will be added. If outcome satura-
tion is still not reached, the search will be extended to 
include studies from 2013 to 2014 and so forth until 
outcome saturation is reached. Examining all available 
literature without a time window is resource intensive and 
may not yield important additional outcomes.
Search strategy
Using a comprehensive search strategy, the following 
databases will be searched for relevant studies: MEDLINE, 
Embase, Web of Science, Cochrane Library and CINAHL. 
Key terms used to guide the search will include ‘GDM’, 
‘gestational diabetes’, ‘maternal diabetes’, ‘hypergly-
cemia’, ‘pregnancy’, ‘prevention’ and ‘treatment’, 
combined as appropriate using the Boolean operands 
‘AND’ and ‘OR’. Online supplementary appendix S1 
outlines a sample search strategy. The reference lists of all 
relevant studies will be searched for additional relevant 
studies not retrieved from the electronic database search. 
Selection of articles will be restricted to English language 
publications.
types of studies
We will include randomised trials and systematic reviews 
of randomised trials (with and without meta- analyses) 
comparing the effectiveness of various interventional 
strategies for both prevention and treatment of GDM.
types of interventions
1. Pharmacological interventions for prevention and 
treatment of GDM.
2. Non- pharmacological interventions for prevention 
and treatment of GDM.
types of participants
Participants will be women over the age of 16 years who 
are:
1. Diagnosed with GDM or
2. At risk of GDM. Women at risk of developing GDM 
include those with a family history of diabetes, over-
weight or having obese body mass index, previous 
GDM and high- risk ethnicity.24
Assessment for eligibility
The titles and abstracts of the retrieved studies will be 
screened and reviewed by two reviewers independently. 
Full texts of potential studies will be assessed for eligi-
bility. In case of uncertainty regarding inclusion at 
title and abstract screening, a third reviewer will be 
consulted.
data extraction
The following data will be extracted from each study: 
study design, author details, year and journal of publica-
tion, targeted condition, criteria for diagnosis of GDM, 
interventions under investigation and all outcomes as 
reported in the trial (including definitions, tools for 
measurement, thresholds and time points).
Two review authors will extract outcomes independently 
and compare and agree on the outcomes extracted. 
Disagreement will be resolved through discussion with a 
third reviewer.
data analysis and presentation
Studies will be divided into those for prevention and 
those for treatment of GDM. Outcomes measured in each 
study will be displayed. Then, outcomes will be further 
grouped under three major domains: maternal outcomes, 
offspring outcomes (to include neonatal, infant, child 
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e-delphi survey
A e- Delphi survey consisting of a series of rounds of data 
collection and analysis to reconcile the opinions of partic-
ipants into a group consensus will be conducted. We will 
conduct a three- round, online e- Delphi survey. Custer et 
al (1999) have recommended that three iterations are 
sufficient to collect necessary information to reach a 
consensus.25
Participants will be provided with the objectives of the 
study and asked for their consent. Participants who agree 
to participate in the study will be asked to score each of 
the outcomes contained within the two lists (GDM preven-
tion and treatment) using a a 9- point Likert scoring scale 
with 1 to 3 labeled ‘not important’, 4 to 6 ‘important but 
not critical’ and 7 to 9 ‘critical’. An option of ‘unable to 
score’ will also be included. This system is recommended 
by the Grading of Recommendations Assessment, Devel-
opment and Evaluation working group for assessing the 
level of importance about research evidence.26 This scale 
has been adopted in other core outcome development 
research groups using the Delphi method. The question-
naire will be completed online using online survey design 
software and data collected will be downloaded and main-
tained on a secure drive.
research participants
We have identified three broad key stakeholder groups 
who will be invited to participate in the e- Delphi survey 
and in the later consensus meeting:
1. Pregnant women at risk of GDM, with GDM or women 
with a previous history of GDM.
2. Healthcare professionals who care for women with 
GDM including obstetricians, endocrinologists, gen-
eral practitioners, midwives, nurse specialists, paediat-
rics, neonatologist, pharmacists, physiotherapists and 
dieticians.
3. Researchers and policy makers with an active interest 
in the prevention and treatment of GDM.
All participants will be 18 years or older.
Sample size and recruitment
There is an absence of guidance on optimal sample sizes 
for e- Delphi surveys, but our intention is to recruit as 
many representatives as possible from each stakeholder 
group from as many countries as possible. The survey will 
be presented in English and therefore only those who can 
complete the survey in English will be able to participate. 
We will aim for a minimum of 20 participants from each 
stakeholder group in round 1.
Process for recruiting participants
Potential participants will be recruited via email from a 
wide range of clinical, health and community settings. 
Recruitment will include listed groups of diabetes 
services users (eg, Diabetes Ireland) accessed via the 
electronic discussion email list manager. The manager 
will be emailed the survey information with a request 
to distribute an invitation email to members on their 
email lists. The list managers will have an opportunity 
to contact the researcher directly to clarify any issues 
or to seek further information about the survey and the 
research before making a decision. The distribution 
of the survey will be at the discretion of the email list 
manager. Clinicians and researchers will be invited from 
specialist centres globally and through the International 
Diabetes in Pregnancy Study Group and Diabetic Preg-
nancy Study Group). These clinical leads will be invited 
to participate by email and will be asked to forward the 
study details to colleagues and patient representatives 
who meet the inclusion criteria. Snowball sampling will 
be used, whereby the participants will be asked to forward 
the invitation to others whom they regard as having the 
required expertise. We aim to recruit participants from a 
minimum of 20 countries.
Detailed participant information will be included on 
the invitation email. This information will include an 
outline on the objectives of the study, the stakeholder 
groups, the estimated length of the survey and the round 
1 survey link. After clicking on the survey link, partici-
pants will be again presented with the study information 
on the survey homepage and asked the following ques-
tion to obtain consent if you are happy to participate in 
this study, please click ‘yes’ to continue’. Participants who 
agreed to participate will be encouraged to complete the 
whole e- Delphi process; yet, they are free to withdraw 
from the study at any point.
To reduce the attrition rate, the importance of 
completing all three rounds will be emphasised and up to 
two reminder emails will be sent after each round launch 
with details of current response rates. If a small number 
of responders is observed in one or more of the three 
stakeholder groups, the e- Delphi protocol for subsequent 
rounds will be reviewed and revised. If a low number of 
responders is observed in one stakeholder group, we will 
consider grouping them with another stakeholder group 
if it is appropriate to do so and after consultation with 
members of the SAG. Attrition bias will be examined 
between rounds to ensure that participants staying in 
have scored outcomes similar to those leaving the study, 
thereby having no impact on the final results.
round 1 e-delphi study
The round 1 instrument will request participant details as 
follows: name, gender identity, country of residence and 
email address. Consent to participate will be obtained 
as described above. Participants will be asked to identify 
the stakeholder group that most represents their stake-
holding perspective.
The two lists of outcomes generated from stage 1 will 
be presented and participants will be asked to rank the 
importance of each outcome for inclusion in the respec-
tive COS on a 9- point Likert scale from 1 to 9 wherein 
1 signifies ‘not important’ and 9 signifies ‘critical’. This 
scale has been used previously in the development of a 
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Table 1 e- Delphi consensus definition
Consensus in Consensus that outcome should be 
included in the core outcome set (COS)
≥70% participants scoring 7 to 9 AND <15% 
participants scoring 1 to 3
Consensus out Consensus that outcome should not be 
included in the COS
≤50% participants scoring 7–9 in each 
stakeholder group
No consensus Uncertainty about importance of the 
outcome
Anything else
alphabetically to avoid weighting of outcomes caused by 
the order in which they are displayed.
An open question will be placed at the end of the 
questionnaire where participants can include up to two 
additional outcomes for GDM prevention studies and 
two additional outcomes for GDM treatment studies 
that were not captured in the list presented. The respon-
dents will be asked only to suggest additional outcomes 
if they believe they are essential to for inclusion in the 
final COSs. This may identify outcomes associated with 
the most recent treatments available or the most pressing 
current concerns for stakeholders that the literature did 
not include. Any additional outcome listed by two or 
more participants will be reviewed by two researchers and 
will be included for rating in round 2 if the additional 
outcome represents a de novo outcome. The need for 
more than two participants will be reviewed if recruit-
ment is lower than expected.
The results of round 1 will be analysed using descriptive 
statistics, including the proportion of each stakeholding 
group scoring for each rating point on the Likert scale 
(ie, for each point from 1 to 9). The number of partic-
ipants taking part will be recorded. Participants will be 
asked to complete the survey within a time scale, which 
will be informed by a pilot study as outlined below. Up to 
two reminder emails will be sent after the first email to 
reduce the attrition rate.
Where any survey is incomplete, the respondent will be 
contacted to encourage completion. The survey will be 
written in plain language terms, developed in conjunc-
tion with the SAG to facilitate patient understanding. All 
participants will complete the same survey. Those who 
do not respond to the invitation email will not be further 
contacted.
Pilot study
We will pilot the first round questionnaire to ensure 
that it is practical and easy to use and to decide on the 
time taken for participants to complete a round of the 
e- Delphi survey.
round 2 e-delphi study
Only participants who completed the questionnaire in 
round 1 will be invited to participate in round 2. Each 
participant will be provided with his/her individual 
ratings for each outcome in round 1 and with the distri-
bution of scores of each outcome from the three stake-
holder groups separately. They will then be asked to 
provide their name and email and re- rate each outcome 
with consideration of the insights of other participants 
from the three stakeholder groups. They will have the 
opportunity to change their response from the previous 
round.
The results of round 2 will be summarised using 
descriptive statistics. The number of participants taking 
part will be recorded. For each outcome, the distribu-
tion of scores for each point in the Likert scale will be 
calculated for each stakeholder group. Consistent with 
other studies using the Delphi approach, prespecified 
criteria, ‘consensus criteria’, will be used for outcomes to 
be retained or dropped at the end of this round. Each 
outcome will be classified as ‘consensus in’, ‘consensus 
out’ or ‘no consensus’ according to the classification 
in table 1. All outcomes scored as ‘consensus in’ will be 
carried forward to round 3.
round 3 e-delphi study
The round 3 questionnaire will be forwarded to partic-
ipants who completed rounds 1 and 2. As in round 2, 
each participant will be provided with his/her individual 
ratings for each outcome in round 2 and with the propor-
tion of scores of each outcome from the three stakeholder 
groups separately alongside his/her own score from 
round 2. Participants will be asked to provide their name 
and email and re- rate each outcome again as in round 2.
The results of round 3 will be summarised using descrip-
tive statistics. The number of participants taking part will 
be recorded. For each outcome, the distribution of scores 
for each point in the Likert scale will be recorded. Each 
outcome will be classified as ‘consensus in’, ‘consensus 
out’ or ‘no consensus’ according to the classification 
in table 1. All outcomes scored as ‘consensus in’ or ‘no 
consensus’ will be carried forward to the consensus 
meeting.
Consensus meeting
A consensus face- to- face meeting will be held with the 
representatives from each of the three stakeholder 
groups at a location agreed by the SAG. We anticipate 
a total number of 15–20 representatives and will aim to 
include representatives from different countries and at 
least five representatives from each of the stakeholder 
groups. The meeting will be facilitated by an experi-
enced, non- voting chair facilitator. Results from the 
e- Delphi will be presented. Participants will have the 
opportunity to voice their opinion on whether an item 
should be excluded or included if the outcome reached 
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outcomes reached ‘no consensus’, further discussion 
will take place. Outcomes may be combined based on 
this group discussion.
Following the discussion on each outcome, partici-
pants will be asked to anonymously vote for inclusion or 
exclusion and ‘consensus in criteria’ from table 1 will be 
used to decide if an outcome is included. At the end of 
the meeting, the recommended lists of outcomes will be 
reviewed and a consensus document with the two COSs 
will be drafted following completion of the consensus 
meeting.
Identifying existing work
WOMen and Babies health and wellbeing: Action through 
Trials initiative has developed ‘standard outcomes’ 
covering prevention, detection, management and 
follow- up in GDM research. A survey completed after the 
development of these standard outcomes revealed signif-
icant discrepancies in outcomes prespecified in reviews 
and reported by randomised trials with the authors 
calling for the development of a COS to reduce research 
waste and improve health outcomes.27 This current study 
will include a broad range of views in the methodology 
and will fulfil the specific focus on developing COSs in 
the realm of GDM.
The final COSs will define ‘what is to be collected’ and 
not ‘how it is to be collected’. In the field of diabetes and 
pregnancy, there exists a previously published repository 
of definitions that may be referenced and we anticipate 
publishing definitions from this repository alongside the 
final COSs where possible.28
The final COS will be reported in compliance with 
COS- STAR recommendations.29
One of the challenges associated with development of 
COS will be ensuring that other research groups take up 
its use. Presenting this project at scientific conferences 
and scheduling additional meetings of researchers in 
the research area of GDM at national and international 
conferences will further increase the uptake of the 
proposed COSs. In addition, the authors will actively 
engage with the Cochrane Pregnancy and Childbirth 
Group to promote awareness of the COSs.
While we will make an effort to ensure that representa-
tives from low and middle income countries are invited 
to participate in each stage of the COS development, this 
has been a challenge in previous COS studies and may 
limit the relevance of the final COSs to these countries. 
In addition, our literature search, e- Delphi and consensus 
meetings will be limited to the English language, which 
may exacerbate this issue. In keeping with available 
resources, we have not planned a qualitative dimension to 
our study, which could have the potential to enhance this 
work. While we acknowledge that this is not the same as 
qualitative research, we will give the opportunity to repre-
sentatives within the SAG to provide feedback on the lists 
of outcomes. This approach is suggested by COMET as an 
alternative to qualitative research.21
ConCluSIon
It is anticipated that the proposed COSs will provide an 
evidence- based and consensus- driven guidance for future 
GDM trials that evaluate interventions for the prevention 
and treatment of GDM.
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